Lisocabtagene maraleucel for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma


featured image

Lisocabtagene maraleucel is in clinical development as a treatment option for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). CLL is a type of cancer that affects white blood cells and tends to progress slowly over many years. It mostly affects people over the age of 60.

Year: 2022

Lisocabtagene maraleucel is in clinical development as a treatment option for chronic lymphocytic
leukaemia (CLL) or small lymphocytic lymphoma (SLL). CLL is a type of cancer that affects white
blood cells and tends to progress slowly over many years. It mostly affects people over the age of 60. CLL and SLL are different forms of the same cancer in which the bone marrow produces too
many white blood cells (lymphocytes), which are not fully developed and fail to work properly. In
SLL, cells build up in the lymph nodes, whereas in CLL the cancer cells can be found in the blood
and bone marrow. Over time this can cause a range of problems, such as an increased risk of
developing infections, persistent tiredness, swollen glands in the neck, armpits or groin, and unusual
bleeding or bruising. Most patients develop resistance to the currently available treatment options,
creating a need for novel therapies for this condition.